Uveitic Glaucoma – A Complete Patient‑Friendly Guide

Overview

Uveitic glaucoma is a form of secondary glaucoma that develops as a complication of uveitis, an inflammation of the uvea (the middle layer of the eye that includes the iris, ciliary body, and choroid). Inflammation or its treatment can obstruct the eye’s fluid‑draining pathways, causing intra‑ocular pressure (IOP) to rise and damage the optic nerve.

• Who it affects: Adults of any age, but most cases occur in people aged 20‑60 years. Both men and women are equally susceptible.
• Prevalence: Uveitis affects ~50‑100 cases per 100,000 people worldwide, and up to 20‑30 % of chronic uveitis patients develop glaucoma over a 5‑year period.^[1][2]
• Geographic variation: Higher rates are reported in regions where infectious uveitis (e.g., tuberculosis, syphilis, toxoplasmosis) is common.

Symptoms

The signs of uveitic glaucoma may overlap with those of uveitis alone, making careful monitoring essential.

• Vision changes – blurred vision, halos around lights, or sudden loss of visual acuity.
• Eye pain – dull ache or throbbing, often worse with eye movement.
• Redness – typically a deep, “ciliary” redness around the iris rather than the superficial conjunctiva.
• Photophobia – discomfort in bright light due to iris inflammation.
• Headache – especially around the forehead or behind the eyes.
• Floating spots (floaters) – may signal active inflammation.
• Reduced peripheral vision – a hallmark of glaucoma progression.
• Eye pressure spikes – often felt as a sensation of “pressure” behind the eye.
• Symptoms of treatment side‑effects – dry mouth or skin rash from systemic steroids, for example.

Because some patients experience few or no symptoms until optic nerve damage occurs, regular eye exams are critical for anyone with a history of uveitis.

Causes and Risk Factors

Primary mechanisms

1. Obstruction of the trabecular meshwork by inflammatory cells, fibrin, or peripheral anterior synechiae (PAS) – scar tissue that permanently closes the drainage angle.
2. Steroid‑induced IOP elevation – topical, peri‑ocular, or systemic corticosteroids, frequently used to control uveitis, can raise pressure in up to 30 % of patients.^[3]
3. Structural changes – chronic inflammation can thicken the ciliary body, reducing aqueous outflow.

Risk factors

• History of chronic or recurrent uveitis (especially anterior uveitis).
• Use of high‑dose or long‑term corticosteroids.
• Age < 40 years when uveitis is severe.
• Underlying systemic autoimmune disease (e.g., sarcoidosis, Behçet’s disease, ankylosing spondylitis).
• Infectious causes that produce heavy inflammatory debris (e.g., tuberculous uveitis).
• Family history of glaucoma or known ocular hypertension.

Diagnosis

Diagnosing uveitic glaucoma requires confirming both active or past uveitis and an elevated IOP that threatens the optic nerve.

Clinical examination

• Slit‑lamp biomicroscopy – assesses anterior chamber cells/flare, presence of keratic precipitates, and angle status.
• Gonioscopy – visualizes the drainage angle for PAS, peripheral anterior synechiae, or angle recession.
• Fundus examination – evaluates optic nerve cupping, hemorrhages, and retinal changes.

Diagnostic tests

Test	Purpose
Tonometry (Goldmann applanation)	Measures intra‑ocular pressure; >21 mmHg is generally abnormal.
Optical Coherence Tomography (OCT)	Quantifies retinal nerve fiber layer (RNFL) thickness; progressive thinning signals glaucoma damage.
Visual field testing (Humphrey 24‑2)	Detects functional loss, especially peripheral defects.
Ultrasound Biomicroscopy (UBM)	Provides high‑resolution images of the angle when gonioscopy is limited.
Blood/serologic tests	Identify systemic causes (e.g., HLA‑B27, ACE for sarcoidosis, VDRL for syphilis).

Diagnosis is usually made by an ophthalmologist specializing in uveitis or glaucoma. A documented history of uveitis plus IOP >21 mmHg with optic nerve changes confirms uveitic glaucoma.

Treatment Options

Management aims to control inflammation, lower IOP, and preserve vision. Treatment is often individualized and may involve a combination of medications, laser procedures, and surgery.

1. Controlling Uveitis

• Topical corticosteroids (e.g., prednisolone acetate 1 %) – first line for anterior uveitis.
• Periocular or intravitreal steroids (triamcinolone acetonide) – for refractory cases, with careful IOP monitoring.
• Systemic immunosuppressants – methotrexate, mycophenolate mofetil, azathioprine, or biologics (adalimumab, infliximab) for chronic or posterior uveitis.^[4]
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – topical ketorolac can reduce mild inflammation without raising IOP.

2. Lowering Intra‑ocular Pressure

Medical therapy

• Prostaglandin analogues (latanoprost, bimatoprost) – most effective for IOP reduction; caution in patients with active inflammation as they may exacerbate uveitis in rare cases.
• Beta‑blockers (timolol, betaxolol) – reduce aqueous production; avoid in asthmatics or severe COPD.
• Alpha‑agonists (brimonidine) – both decrease production and increase outflow.
• Carbonic anhydrase inhibitors (dorzolamide, oral acetazolamide) – useful adjuncts, especially in acute pressure spikes.
• Rho‑kinase inhibitors (netarsudil) – emerging agents with good outflow‑enhancing properties.

Laser therapy

• Selective laser trabeculoplasty (SLT) – first‑line laser option; can be performed even with mild inflammation.
• Laser peripheral iridotomy – indicated if secondary angle‑closure components develop (e.g., due to iris bombe).

Surgical interventions

When medical and laser measures fail to maintain target IOP (<15–18 mmHg), surgery is considered.

• Trabeculectomy with antimetabolites (MMC/5‑FU) – creates a new drainage pathway; higher failure rates in inflamed eyes, so surgery is often delayed until inflammation is quiescent.
• Glaucoma drainage devices (e.g., Ahmed, Baerveldt) – preferred in eyes with extensive synechiae or prior surgeries.
• Cyclodestructive procedures (trans‑scleral cyclophotocoagulation) – reserved for refractory cases; can lower IOP by reducing aqueous production.
• Minimally invasive glaucoma surgery (MIGS) – angle‑based devices (e.g., iStent) are being studied; limited data in active uveitis.

3. Lifestyle & Adjunctive Measures

• Maintain a regular follow‑up schedule – at least every 3–4 months for stable disease; more frequent during flares.
• Adopt a low‑salt diet and stay well‑hydrated to avoid systemic fluid shifts that can affect eye pressure.
• Limit caffeine intake (excess caffeine may transiently raise IOP).
• Protect eyes from bright light with sunglasses to reduce photophobia.
• Discuss smoking cessation with your provider; smoking worsens inflammatory responses.

Living with Uveitic Glaucoma

Daily management tips

1. Medication adherence – use a pill/eye‑drop organizer; set alarms to avoid missed doses.
2. Carry a list of all eye drops, oral meds, and recent lab results; share with any new health‑care provider.
3. Monitor vision – perform a quick “Amsler grid” test weekly; note any new dark spots, lines, or blurry areas.
4. Protect your eyes – wear UV‑blocking sunglasses and safety eyewear during sports or work.
5. Stay active – moderate exercise (e.g., walking) improves ocular blood flow without raising IOP.
6. Manage stress – chronic stress can aggravate autoimmune uveitis; consider yoga, meditation, or counseling.
7. Plan for travel – bring extra medication, keep them in original containers, and know the location of an ophthalmology clinic at your destination.

Emotional support

Living with a chronic eye disease can be anxiety‑provoking. Support groups (e.g., Glaucoma Support Network, Uveitis Society) and counseling services are valuable resources.

Prevention

While not all cases are preventable, several strategies reduce the likelihood of developing uveitic glaucoma or worsening existing disease:

• Prompt treatment of uveitis – early control of inflammation lowers the chance of angle damage.
• Use the lowest effective steroid dose – work with your ophthalmologist to taper steroids as soon as inflammation is controlled.
• Regular IOP checks – especially after initiating or increasing steroid therapy.
• Screen for systemic disease – early identification of underlying autoimmune or infectious causes enables targeted therapy.
• Vaccinations – stay up to date (e.g., influenza, shingles) to avoid infections that can trigger uveitis.
• Healthy lifestyle – balanced diet rich in omega‑3 fatty acids, regular exercise, and smoking cessation help modulate immune responses.

Complications

If left untreated or inadequately managed, uveitic glaucoma can lead to serious ocular and systemic sequelae:

• Permanent vision loss – optic nerve damage is irreversible; severe cases can result in blindness.
• Secondary cataract – both chronic inflammation and corticosteroid use accelerate lens opacity.
• Macular edema – fluid accumulation in the central retina further impairs visual acuity.
• Corneal decompensation – chronic high IOP can cause endothelial cell loss and corneal swelling.
• Persistent ocular pain – due to uncontrolled pressure or inflammation.
• Psychosocial impact – decreased quality of life, loss of independence, and increased risk of depression.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Uveitis.” Updated 2023. https://www.mayoclinic.org
2. World Health Organization. “Global prevalence of uveitis.” WHO Bulletin 2022;100(5):230‑237.
3. National Eye Institute (NEI). “Steroid‑induced glaucoma.” 2021. NEI
4. Cleveland Clinic. “Immunosuppressive therapy for uveitis.” 2024. Cleveland Clinic
5. American Academy of Ophthalmology. Preferred Practice Pattern: Glaucoma, 2023. AAO